Drug Importation in New Mexico: An Overview
New Mexico published the draft of its application to the U.S. Department of Health and Human Services on Oct. 29, 2020 with intent to submit to HHS by Dec. 15, 2020. Consult PSM's ongoing analysis on the right to learn more about their proposed plans.
- N.M. May Get Med Imports From Canada Under Trump Order, September 25, 2020
"An outline of the program must be submitted by Dec. 15 to the U.S. Health and Human Services Department, Morgan said, adding that the public will have a chance to comment on the program before then."
Ongoing Analysis of New Mexico's Application to HHS
The application is over 4,000 pages, so as we produce analysis or we find analysis from others, we are publishing it here. Read the October 2020 application draft, appendix, and notice of public meeting.
To get up to speed, read What is Drug Importation? A short primer and guide to keeping New Mexico residents safe and learning the myths of Canadian drug importation.
Watch our video and read the accompanying blog to hear our analysis of New Mexico's draft application.
Recent Statements Opposing Canadian Drug Importation
- American Pharmacists Association
- Canadian Pharmacists Association
- American Society of Health-System Pharmacists
- Canadian Society of Hospital Pharmacists
- National Association of Boards of Pharmacy
- Canadian Association for Pharmacy Distribution Management
Prescription Drugs in Wyoming, Evaluating State Policy Options For Lowering Costs (October 1, 2020)
The Wyoming Department of Health concluded that it is "virtually impossible to guarantee that consumers will actually see savings, particularly in the case of Canadian drug importation. Basic economics also suggests fundamental problems with this plan that make it unsustainable in the long-run."
Learn more about
Op-eds from the Experts
This editorial by Brandon Macsata was published in The International Business Times on November 1, 2020. Macsata has been living with HIV since 2002, and serves as the CEO of the ADAP Advocacy Association, an organization that promotes the AIDS Drug Assistance Program and works to improve access to care.
In this October 23, 2020 editorial, which was published in the The American Journal of Managed Care, Michael Abrams explains why drug importation will not save patients money. Abrams is the co-founder and managing partner of Numerof & Associates.
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
In the first seven months of 2020, the Arizona Department of Health Services reported over 2,700 newly suspected opioid overdose deaths in Arizona. What makes this figure more startling is that there were just over 3,800 suspected opioid deaths in the preceding 30 months. The problem is escalating, and rapidly.
The editorial board of the Florida Times-Union published an op-ed that states that Canadian drug importation will have a limited impact, and is a sign of a broken system, not a solution to one…
In this editorial, which was published in WBUR’s Cognoscenti on September 2, 2020, writer Sarah Ruth Bates explains why Canadian drug importation is too expensive and elaborate a solution to be effective.
In this editorial, Louisiana Attorney General Jeff Landry warns parents and students about the dangers posed by counterfeit pills being sold on college campuses.
In this August 14, 2020 editorial, Best Medicines Coalition chair John Adams explains why Canadian importation will not lower U.S. medicine prices—and why the “concept of cheap drugs from Canada has never been anything more than a political hallucination.”
In this July 28, 2020 editorial published in the WasteWatcher blog, Elizabeth Wright argues that the administration’s Executive Order will “encourage more illegal behavior and a greater production of counterfeit drugs from countries like China, Mexico, and India.” Wright is the Director of Health and Public Policy for Citizens Against Government Waste
This editorial by Andrew Spiegel was published in The International Business Times on March 23, 2020. Mr. Spiegel is executive director of the Global Colon Cancer Association and Chair of the World Patient Alliance. President Trump, Price Controls Can’t Combat Coronavirus The U.S. outbreak of novel coronavirus, COVID-19, has quickly evolved into a national nightmare.…